Seres Therapeutics, Inc

(NASDAQ:MCRB)

Latest On Seres Therapeutics, Inc (MCRB):

Date/Time Type Description Signal Details
2023-05-30 17:25 ESTNewsSeres receives $125M milestone payment for FDA Approval of Vowst for C. difficile InfectionN/A
2023-05-23 14:58 ESTNewsSeres Q1 Earnings: Major News For InvestorsN/A
2023-05-23 00:11 ESTNewsSeres Therapeutics: Still Work To Do Before Realizing Its PotentialN/A
2023-05-09 15:43 ESTNewsSeres Therapeutics GAAP EPS of -$0.57 misses by $0.02N/A
2023-05-09 15:42 ESTNewsSeres Therapeutics, Inc. (MCRB) Q1 2023 Earnings Call TranscriptN/A
2023-05-09 01:59 ESTNewsSeres Therapeutics Q1 2023 Earnings PreviewN/A
2023-05-03 13:01 ESTNewsSeres Gets FDA Approval And The Share Price Goes Down!N/A
2023-04-27 07:33 ESTNewsSeres adds 11% on FDA nod microbiome therapyN/A
2023-04-22 20:35 ESTNewsStocks To Watch: Microsoft, Amazon And Coca-Cola Headline Huge Earnings WeekN/A
2023-04-17 23:40 ESTNewsSeres hits four-month high ahead of FDA decision on lead assetN/A
2023-04-06 00:47 ESTNewsSeres Therapeutics: Binary Catalyst UnlockingN/A
2023-03-07 21:52 ESTNewsSeres Therapeutics GAAP EPS of -$2.31 misses by $0.15, revenue of $7.13M misses by $6.62MN/A
2023-03-07 21:52 ESTNewsSeres Therapeutics falls 9% on full-year earnings missN/A
2023-03-07 21:51 ESTNewsSeres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call TranscriptN/A
2023-03-06 16:34 ESTNewsSeres Therapeutics FY 2022 Earnings PreviewN/A
2023-02-06 20:00 ESTNewsSeres Therapeutics: FDA Approval Straight AheadN/A
2023-02-05 18:02 ESTNewsThe Clock Is Ticking For Seres Therapeutics: I'm Not AfraidN/A
2022-12-09 21:16 ESTNewsSeres Therapeutics (MCRB) Investor Presentation - SlideshowN/A
2022-11-10 19:57 ESTNewsSeres Gets Closer To Good TimesN/A
2022-11-02 20:10 ESTNewsSeres Therapeutics GAAP EPS of -$0.49 misses by $0.02, revenue of $3.44M misses by $3.57MN/A
2022-11-02 20:10 ESTNewsSeres stock sinks as Q3 plunges in lossN/A
2022-11-02 20:10 ESTNewsSeres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call TranscriptN/A
2022-10-26 19:58 ESTNewsSeres microbiome therapy for bacterial infection gets FDA priority reviewN/A
2022-09-07 21:20 ESTNewsSeres completes regulatory submissions seeking FDA nod for lead assetN/A
2022-08-20 04:43 ESTNewsSeres Therapeutics: What The Market Is MissingN/A
2022-08-03 23:17 ESTNewsSeres rises 16% as co expects to file BLA for C. difficile infection treatment in coming weeksN/A
2022-08-03 23:17 ESTNewsSeres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-03 08:18 ESTNewsSeres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22MN/A
2022-07-13 04:02 ESTNewsSeres Therapeutics: The Good And The ChallengingN/A
2022-06-30 13:41 ESTNewsSeres Therapeutics stock slips on $100M stock offeringN/A
2022-06-11 04:19 ESTNewsSeres Therapeutics: The Pipeline Is The ProblemN/A
2022-06-09 19:45 ESTNewsSeres Therapeutics: As Biotech Fades, The Case For The Company's Investment StrengthensN/A
2022-06-07 14:32 ESTNewsSeres Therapeutics posts additional safety data for lead candidateN/A
2022-05-05 06:07 ESTNewsSeres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 09:15 ESTNewsSeres Therapeutics GAAP EPS of -$0.61 misses by $0.09, revenue of $1.49MN/A
2022-05-03 17:34 ESTNewsSeres Therapeutics Q1 2022 Earnings PreviewN/A
2022-03-06 11:37 ESTNewsSeres Therapeutics Is Playing A Long GameN/A
2022-03-02 20:11 ESTNewsSeres Therapeutics (MCRB) Presents At Chardan's Microbiome and Metagenomics Summit - SlideshowN/A
2022-03-02 03:42 ESTNewsSeres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-01 09:35 ESTNewsSeres Therapeutics GAAP EPS of -$0.72 misses by $0.10, revenue of $144.92M misses by $4.9MN/A
2022-01-20 06:51 ESTNewsSeres late-stage data on microbiome therapy shows efficacy against C. difficile infectionN/A
2021-12-01 04:59 ESTNewsSeres Therapeutics at a four-month high after update on study for microbiome drugN/A
2021-11-11 09:21 ESTNewsSeres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-11 09:21 ESTNewsSeres Therapeutics shares surge 30% after Q3 earnings beatN/A
2021-11-10 11:48 ESTNewsSeres Therapeutics EPS beats by $0.75, beats on revenueN/A
2021-11-10 11:47 ESTNewsSeres Therapeutics and Bacthera ink collaboration agreementN/A
2021-11-10 11:47 ESTNewsRed Light For Seres Therapeutics, But Not A Stop Light For MeN/A
2021-11-09 12:47 ESTNewsSeres Therapeutics Q3 2021 Earnings PreviewN/A
2021-10-04 08:40 ESTNewsSeres Therapeutics reports data from late-stage SER-109 study at IDWeek2021N/A
2021-10-04 08:38 ESTNewsSeres Therapeutics Molecular Data On SER-109 Looks GoodN/A

About Seres Therapeutics, Inc (MCRB):

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

See Advanced Chart

General

  • Name Seres Therapeutics, Inc
  • Symbol MCRB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 155
  • Fiscal Year EndDecember
  • IPO Date2015-06-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.serestherapeutics.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 48.74
  • Price/Book (Most Recent Quarter) 10.63
  • Enterprise Value Revenue 49.52
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.42
  • Next Year EPS Estimate -$1.30
  • Next Quarter EPS Estimate -$0.31
  • Profit Margin -268%
  • Operating Margin -265%
  • Return on Assets -23%
  • Return on Equity -141%
  • Revenue 33.22 million
  • Earnings Per Share -$1.87
  • Revenue Per Share $0.42
  • Gross Profit -57355000
  • Quarterly Earnings Growth 130.4%
View More

Highlights

  • Market Capitalization 1.9 billion
  • EBITDA -69997000
  • PE Ratio -0.75
  • PEG Ratio -0.11
  • Analyst Target Price $37.57
  • Book Value Per Share $1.91
View More

Share Statistics

  • Shares Outstanding 91.55 million
  • Shares Float 68.32 million
  • % Held by Insiders 926%
  • % Held by Institutions 81.2%
  • Shares Short 6.56 million
  • Shares Short Prior Month 5.96 million
  • Short Ratio 7.17
  • Short % of Float 12%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • Beta 3.96
  • 52 Week High $38.5
  • 52 Week Low $3.01
  • 50 Day Moving Average 22.75
  • 200 Day Moving Average 26.66
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Seres Therapeutics, Inc (MCRB) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Seres Therapeutics, Inc (MCRB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$17.56 million-$0.19-$0.2832.14%
2020-09-302020-11-09$N/A-$0.36-$0.26-40.46%
2020-06-302020-07-28$6.05 million-$0.28-$0.26-8.28%
2020-03-312020-05-07$8.19 million-$0.28-$0.26-7.69%
2019-12-312020-03-02$7.62 million-$0.25-$0.2810.17%
2019-09-302019-11-05$7.03 million-$0.23-$0.2818.35%
2019-06-302019-08-06$12.53 million-$0.24-$0.4850.39%
2019-03-312019-05-02$7.32 million-$0.59-$0.44-33.57%
2018-12-312019-03-06$10.63 million-$0.52-$0.6924.91%
2018-09-302018-11-08$9.06 million-$0.54-$0.6314.83%
2018-06-302018-08-02$4.61 million-$0.68-$0.725.78%
2018-03-312018-05-09$3.97 million-$0.69-$0.769.69%
2017-12-312018-03-08$3.06 million-$0.72-$0.754.18%
2017-09-302017-11-08$23.02 million-$0.17-$0.5669.64%
2017-06-302017-08-03$3.01 million-$0.69-$0.64-8.15%
2017-03-312017-05-04$3.02 million-$0.63-$0.664.79%
2016-12-312017-03-16$3.04 million-$0.64-$0.7514.29%
2016-09-302016-11-10$13.02 million-$0.46-$0.5617.37%
2016-06-302016-08-11$3 million-$0.70-$0.45-55.56%
2016-03-312016-05-16$2.71 million-$0.50-$0.48-4.89%
2015-12-312016-02-25$N/A-$0.41-$0.433.53%
2015-09-302015-11-10$N/A-$0.38-$0.32-18.75%
2015-06-302015-07-01$N/A-$1.45-$0.30-383.33%

Seres Therapeutics, Inc (MCRB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Seres Therapeutics, Inc (MCRB) Chart:

Seres Therapeutics, Inc (MCRB) News:

Below you will find a list of latest news for Seres Therapeutics, Inc (MCRB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Seres Therapeutics, Inc (MCRB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-200.50CALL0 00TRUE00
2025-06-2010CALL0 00TRUE00
2025-06-201.50CALL0 00TRUE00
2025-06-2020CALL0 00TRUE00
2025-06-202.50CALL0 01122.98TRUE00
2025-06-2050CALL0 0118.54TRUE00
2025-06-207.50.77CALL1 085.49FALSE0.770
2025-06-20101.5CALL0 6159.05FALSE00
2025-06-2012.50.24CALL2 28194.66FALSE-0.01-0.04
2025-06-20150.1CALL0 9296.98FALSE00
2025-06-2017.50CALL0 0322.76FALSE00
2025-06-20200.1CALL0 5343.3FALSE00
2025-06-200.50PUT0 0581.14FALSE00
2025-06-2010PUT0 00FALSE00
2025-06-201.50PUT0 0789.69FALSE00
2025-06-2020PUT0 0813.92FALSE00
2025-06-202.50PUT0 0601.51FALSE00
2025-06-2050PUT0 0167.67FALSE00
2025-06-207.51.21PUT0 1120.93TRUE00
2025-06-20100PUT0 0137.28TRUE00
2025-06-2012.50PUT0 0159.67TRUE00
2025-06-20150PUT0 0165.08TRUE00
2025-06-2017.50PUT0 0190.07TRUE00
2025-06-202012.6PUT0 1222.15TRUE00
2025-07-180.50CALL0 1040TRUE00
2025-07-1810CALL0 11860TRUE00
2025-07-181.50CALL0 100TRUE00
2025-07-1820CALL0 00TRUE00
2025-07-182.50CALL0 0573.18TRUE00
2025-07-1850CALL0 0121.81TRUE00
2025-07-187.50.05CALL0 0106.31FALSE00
2025-07-18100CALL0 0163.16FALSE00
2025-07-1812.50CALL0 0168.73FALSE00
2025-07-18150CALL0 0164.18FALSE00
2025-07-1817.50CALL0 0240.74FALSE00
2025-07-18200.5CALL0 4258.21FALSE00
2025-07-180.50PUT0 41467.58FALSE00
2025-07-1810PUT0 30564.5FALSE00
2025-07-181.50PUT0 0636.17FALSE00
2025-07-1820PUT0 0655.97FALSE00
2025-07-182.50PUT0 0446.6FALSE00
2025-07-1850PUT0 0177.06FALSE00
2025-07-187.51.75PUT0 1111.4TRUE00
2025-07-18100PUT0 0123.36TRUE00
2025-07-1812.50PUT0 0160.53TRUE00
2025-07-18150PUT0 0146.35TRUE00
2025-07-1817.50PUT0 0184.07TRUE00
2025-07-18200PUT0 0241.66TRUE00
2025-10-170.50CALL0 350TRUE00
2025-10-1710CALL0 780TRUE00
2025-10-171.50CALL0 00TRUE00
2025-10-1720CALL0 1200TRUE00
2025-10-172.50CALL0 0108.47TRUE00
2025-10-1750CALL0 0108.54TRUE00
2025-10-177.50CALL0 090.14FALSE00
2025-10-17100CALL0 0114.29FALSE00
2025-10-1712.50CALL0 0131.91FALSE00
2025-10-17150CALL0 0133.21FALSE00
2025-10-1717.50CALL0 0132.22FALSE00
2025-10-17200CALL0 0121.41FALSE00
2025-10-170.50PUT0 0357.98FALSE00
2025-10-1710PUT0 1408.59FALSE00
2025-10-171.50PUT0 00FALSE00
2025-10-1720PUT0 0451.53FALSE00
2025-10-172.50PUT0 0295.05FALSE00
2025-10-1750PUT0 0130.18FALSE00
2025-10-177.50PUT0 0122.41TRUE00
2025-10-17100PUT0 0113.58TRUE00
2025-10-1712.50PUT0 0131.24TRUE00
2025-10-17158.1PUT0 0158.14TRUE00
2025-10-1717.50PUT0 0120.52TRUE00
2025-10-17200PUT0 0128.75TRUE00
2026-01-160.50CALL0 5030TRUE00
2026-01-1610.05CALL3 10650TRUE0.050
2026-01-161.50CALL0 5650TRUE00
2026-01-1620CALL0 270TRUE00
2026-01-162.50.05CALL0 0124.08TRUE00
2026-01-1630CALL0 120TRUE00
2026-01-163.50CALL0 260TRUE00
2026-01-1640CALL0 00TRUE00
2026-01-164.50CALL0 00TRUE00
2026-01-1650.05CALL0 0107.98TRUE00
2026-01-165.50CALL0 00TRUE00
2026-01-167.50.1CALL0 0103.32FALSE00
2026-01-16100CALL0 094.68FALSE00
2026-01-1612.50CALL0 0113.96FALSE00
2026-01-16152.25CALL0 6120.73FALSE00
2026-01-1617.50CALL0 0118.82FALSE00
2026-01-16200CALL0 0122.05FALSE00
2026-01-160.50PUT0 400FALSE00
2026-01-1610PUT0 153323.01FALSE00
2026-01-161.50PUT0 3348.49FALSE00
2026-01-1620PUT0 5420.56FALSE00
2026-01-162.51.9PUT0 0245.72FALSE00
2026-01-1630PUT0 0420.94FALSE00
2026-01-163.50PUT0 0407.47FALSE00
2026-01-1640PUT0 0417.9FALSE00
2026-01-164.50PUT0 0427.04FALSE00
2026-01-1651.25PUT0 10105.94FALSE00
2026-01-165.50PUT0 0442.56FALSE00
2026-01-167.50PUT0 0113.5TRUE00
2026-01-16100PUT0 0109.9TRUE00
2026-01-1612.50PUT0 0106.94TRUE00
2026-01-16150PUT0 098.02TRUE00
2026-01-1617.50PUT0 0139.23TRUE00
2026-01-16200PUT0 0112.56TRUE00
2027-01-150.50CALL0 6740TRUE00
2027-01-1510CALL0 1030TRUE00
2027-01-151.50CALL0 40TRUE00
2027-01-1520CALL0 150TRUE00
2027-01-152.50CALL0 0133.4TRUE00
2027-01-1550CALL0 098.9TRUE00
2027-01-157.50CALL0 10260FALSE00
2027-01-15100CALL0 0110.23FALSE00
2027-01-1512.50CALL0 0108.81FALSE00
2027-01-15150CALL0 0102.77FALSE00
2027-01-1517.50CALL0 0109.84FALSE00
2027-01-15200CALL0 0115.65FALSE00
2027-01-150.50PUT0 20308.7FALSE00
2027-01-1510PUT0 00FALSE00
2027-01-151.50PUT0 10FALSE00
2027-01-1520PUT0 00FALSE00
2027-01-152.50PUT0 0162.64FALSE00
2027-01-1550PUT0 0130.53FALSE00
2027-01-157.50PUT0 0336.63TRUE00
2027-01-15100PUT0 0109.6TRUE00
2027-01-1512.50PUT0 0109.44TRUE00
2027-01-15150PUT0 0106.93TRUE00
2027-01-1517.50PUT0 0102.47TRUE00
2027-01-15200PUT0 096.35TRUE00

Latest MCRB Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST300$2.765
Jun 13, 2022 7:59 PM EST100$2.765
Jun 13, 2022 7:59 PM EST100$2.76
Jun 13, 2022 7:59 PM EST5$2.76
Jun 13, 2022 7:59 PM EST200$2.765

Seres Therapeutics, Inc (MCRB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320018111/0000899243-20-018111-index.htm
2020-03-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1609809/000000000020002288/0000000000-20-002288-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000021545719006834/0000215457-19-006834-index.htm
2019-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000021545719008320/0000215457-19-008320-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000031506619001315/0000315066-19-001315-index.htm
2019-11-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000031506619001764/0000315066-19-001764-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000031506620001189/0000315066-20-001189-index.htm
2020-09-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000031506620001720/0000315066-20-001720-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000083423720008241/0000834237-20-008241-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018511/0000899243-18-018511-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018512/0000899243-18-018512-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018513/0000899243-18-018513-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018515/0000899243-18-018515-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018518/0000899243-18-018518-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018521/0000899243-18-018521-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018522/0000899243-18-018522-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm
2018-07-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/0000899243-18-019814-index.htm
2018-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318020074/0000899243-18-020074-index.htm
2018-09-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318023727/0000899243-18-023727-index.htm
2018-09-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318023729/0000899243-18-023729-index.htm
2018-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/0000899243-18-023938-index.htm
2018-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318024194/0000899243-18-024194-index.htm
2018-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm
2018-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318026790/0000899243-18-026790-index.htm
2018-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318027398/0000899243-18-027398-index.htm
2018-10-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318027399/0000899243-18-027399-index.htm
2018-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318029310/0000899243-18-029310-index.htm
2018-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/0000899243-18-031411-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319002136/0000899243-19-002136-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319002137/0000899243-19-002137-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319002138/0000899243-19-002138-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319002141/0000899243-19-002141-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319002142/0000899243-19-002142-index.htm
2019-02-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319003202/0000899243-19-003202-index.htm
2019-02-153/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319003843/0000899243-19-003843-index.htm
2019-04-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319011035/0000899243-19-011035-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017010/0000899243-19-017010-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017012/0000899243-19-017012-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017013/0000899243-19-017013-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017016/0000899243-19-017016-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017018/0000899243-19-017018-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017019/0000899243-19-017019-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017029/0000899243-19-017029-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017036/0000899243-19-017036-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017038/0000899243-19-017038-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017640/0000899243-19-017640-index.htm
2019-06-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319018536/0000899243-19-018536-index.htm
2019-08-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319021169/0000899243-19-021169-index.htm
2019-08-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319021170/0000899243-19-021170-index.htm
2019-11-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319028069/0000899243-19-028069-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002210/0000899243-20-002210-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002211/0000899243-20-002211-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002212/0000899243-20-002212-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002213/0000899243-20-002213-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002418/0000899243-20-002418-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002419/0000899243-20-002419-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002420/0000899243-20-002420-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002422/0000899243-20-002422-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002423/0000899243-20-002423-index.htm
2020-03-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320009247/0000899243-20-009247-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320009250/0000899243-20-009250-index.htm
2020-04-073Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320010404/0000899243-20-010404-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320010407/0000899243-20-010407-index.htm
2020-04-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320011277/0000899243-20-011277-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017347/0000899243-20-017347-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017353/0000899243-20-017353-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017354/0000899243-20-017354-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017355/0000899243-20-017355-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017356/0000899243-20-017356-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017357/0000899243-20-017357-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017361/0000899243-20-017361-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017363/0000899243-20-017363-index.htm
2020-07-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320018109/0000899243-20-018109-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320018111/0000899243-20-018111-index.htm
2020-10-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320028908/0000899243-20-028908-index.htm
2020-10-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320028909/0000899243-20-028909-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000095010320002661/0000950103-20-002661-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000110465920021149/0001104659-20-021149-index.htm
2020-10-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000110465920113858/0001104659-20-113858-index.htm
2019-09-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000114036119016287/0001140361-19-016287-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000114036120002975/0001140361-20-002975-index.htm
2020-09-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000114036120019924/0001140361-20-019924-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000114420419007781/0001144204-19-007781-index.htm
2018-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518205796/0001193125-18-205796-index.htm
2018-08-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518235595/0001193125-18-235595-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518240749/0001193125-18-240749-index.htm
2018-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518265488/0001193125-18-265488-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518303575/0001193125-18-303575-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518320919/0001193125-18-320919-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518321819/0001193125-18-321819-index.htm
2018-11-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518331898/0001193125-18-331898-index.htm
2019-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519009357/0001193125-19-009357-index.htm
2019-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519064643/0001193125-19-064643-index.htm
2019-03-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1609809/000119312519065218/0001193125-19-065218-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519070257/0001193125-19-070257-index.htm
2019-04-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519110877/0001193125-19-110877-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1609809/000119312519129317/0001193125-19-129317-index.htm
2019-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1609809/000119312519129353/0001193125-19-129353-index.htm
2019-05-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519133801/0001193125-19-133801-index.htm
2019-06-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312519171388/0001193125-19-171388-index.htm
2019-06-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312519173661/0001193125-19-173661-index.htm
2019-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519173673/0001193125-19-173673-index.htm
2019-06-28SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1609809/000119312519186075/0001193125-19-186075-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519213482/0001193125-19-213482-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519213483/0001193125-19-213483-index.htm
2019-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519283493/0001193125-19-283493-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519284005/0001193125-19-284005-index.htm
2019-11-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312519301823/0001193125-19-301823-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519301827/0001193125-19-301827-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519314364/0001193125-19-314364-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520057817/0001193125-20-057817-index.htm
2020-03-02S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1609809/000119312520058927/0001193125-20-058927-index.htm
2020-03-09S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1609809/000119312520067187/0001193125-20-067187-index.htm
2020-03-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1609809/000119312520074860/0001193125-20-074860-index.htm
2020-03-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312520077200/0001193125-20-077200-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520077213/0001193125-20-077213-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520081498/0001193125-20-081498-index.htm
2020-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1609809/000119312520128784/0001193125-20-128784-index.htm
2020-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1609809/000119312520128794/0001193125-20-128794-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520135559/0001193125-20-135559-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520175590/0001193125-20-175590-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520214096/0001193125-20-214096-index.htm
2020-08-11S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1609809/000119312520216465/0001193125-20-216465-index.htm
2020-08-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312520216509/0001193125-20-216509-index.htm
2020-08-13FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1609809/000119312520217856/0001193125-20-217856-index.htm
2020-08-13FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1609809/000119312520218233/0001193125-20-218233-index.htm
2020-08-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312520220573/0001193125-20-220573-index.htm
2020-08-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312520220574/0001193125-20-220574-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520220584/0001193125-20-220584-index.htm
2020-08-17FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1609809/000119312520222451/0001193125-20-222451-index.htm
2020-08-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1609809/000119312520224776/0001193125-20-224776-index.htm
2019-09-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000121465919005718/0001214659-19-005718-index.htm
2020-09-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000121465920007732/0001214659-20-007732-index.htm
2018-08-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459018018757/0001564590-18-018757-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459018028339/0001564590-18-028339-index.htm
2019-03-0610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1609809/000156459019006423/0001564590-19-006423-index.htm
2019-05-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459019015070/0001564590-19-015070-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459019029069/0001564590-19-029069-index.htm
2019-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459019040255/0001564590-19-040255-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1609809/000156459020008002/0001564590-20-008002-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459020022457/0001564590-20-022457-index.htm
2020-07-2810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459020033715/0001564590-20-033715-index.htm
2020-03-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1609809/999999999520000587/9999999995-20-000587-index.htm
2019-04-15CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1609809/999999999719002897/9999999997-19-002897-index.htm

Seres Therapeutics, Inc (MCRB) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Seres Therapeutics, Inc (MCRB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 926%
Institutional Ownership: 8120%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-10-15John G. AuninsOfficerSell14,279.005.9484,800.13103,811.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318026790/0000899243-18-026790-index.htm
2020-01-26John G. AuninsChief Technology Officer & EVPBuy12,500.00105,250.00https://www.sec.gov/Archives/edgar/data/1609809/000089924320002210/0000899243-20-002210-index.htm
2018-09-17John G. AuninsOfficerSell14,279.007.27103,875.44118,090.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm
2019-11-01Marcus ChapmanOfficerBuy12,000.0012,000.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319028069/0000899243-19-028069-index.htm
2020-01-26Matthew R. HennOfficerBuy7,500.0012,000.00https://www.sec.gov/Archives/edgar/data/1609809/000089924320002211/0000899243-20-002211-index.htm
2019-01-28Eric D. ShaffOfficerSell4,378.005.7525,187.5112,842.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002138/0000899243-19-002138-index.htm
2018-08-15John G. AuninsOfficerSell14,279.007.57108,069.18132,369.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm
2018-05-15John G. AuninsOfficerSell14,279.008.08115,400.02146,648.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm
2019-01-26DAVID N COOKOfficerBuy7,500.00147,435.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002136/0000899243-19-002136-index.htm
2019-01-28Thomas DesRosierChief Legal Officer and EVPSell5,471.005.7531,477.9516,054.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002141/0000899243-19-002141-index.htm
2018-07-15John G. AuninsChief Technology Officer & EVPSell14,279.008.10115,725.58160,927.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318020074/0000899243-18-020074-index.htm
2019-01-26Eric D. ShaffOfficerBuy12,000.0017,220.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002138/0000899243-19-002138-index.htm
2018-09-07Roger PomerantzPresident and CEOSell1,810.009.0016,291.27213,976.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318024194/0000899243-18-024194-index.htm
2019-01-26Thomas DesRosierChief Legal Officer and EVPBuy15,000.0021,525.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002141/0000899243-19-002141-index.htm
2018-09-06Roger PomerantzPresident and CEOSell3,013.009.0427,235.41215,786.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/0000899243-18-023938-index.htm
2018-09-05Roger PomerantzPresident and CEOSell9,505.009.1286,714.12218,799.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/0000899243-18-023938-index.htm
2018-06-25Roger PomerantzPresident and CEOSell26,752.009.21246,503.63228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-26Roger PomerantzPresident and CEOSell21,224.009.19195,133.46228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-27Roger PomerantzPresident and CEOSell16,991.009.03153,408.34228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-28Roger PomerantzPresident and CEOSell21,560.009.15197,375.33228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm
2018-06-29Roger PomerantzPresident and CEOSell4,496.009.1040,915.40228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm
2018-07-06Roger PomerantzPresident and CEOSell15,366.009.14140,506.70228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-09Roger PomerantzPresident and CEOSell10,981.009.14100,350.97228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-10Roger PomerantzPresident and CEOSell5,989.009.0554,207.64228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-11Roger PomerantzPresident and CEOSell1,010.009.019,098.99228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/0000899243-18-019814-index.htm
2018-07-11Roger PomerantzPresident and CEOBuy1,010.000.71717.10229,314.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/0000899243-18-019814-index.htm
2018-06-29Roger PomerantzPresident and CEOBuy4,496.000.713,192.16232,800.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm
2018-07-10Roger PomerantzPresident and CEOBuy5,989.000.714,252.19234,293.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-09Roger PomerantzPresident and CEOBuy10,981.000.717,796.51239,285.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-06Roger PomerantzPresident and CEOBuy15,366.000.7110,909.86243,670.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-06-27Roger PomerantzPresident and CEOBuy16,991.000.7112,063.61245,295.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-26Roger PomerantzPresident and CEOBuy21,224.000.7115,069.04249,528.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-28Roger PomerantzPresident and CEOBuy21,560.000.7115,307.60249,864.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm
2018-06-25Roger PomerantzPresident and CEOBuy16,288.000.7111,564.48255,056.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2020-01-26Eric D. ShaffCEO and PresidentBuy20,000.0032,842.00https://www.sec.gov/Archives/edgar/data/1609809/000089924320002213/0000899243-20-002213-index.htm
2020-01-26Thomas DesRosierChief Legal Officer and EVPBuy25,000.0041,054.00https://www.sec.gov/Archives/edgar/data/1609809/000089924320002212/0000899243-20-002212-index.htm
2019-06-18NOUBAR AFEYANDirectorBuy4,444,444.002.259,999,999.004,444,444.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319017640/0000899243-19-017640-index.htm
2018-12-17John G. AuninsChief Technology Officer & EVPSell14,282.006.3991,313.4075,250.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/0000899243-18-031411-index.htm
2018-12-19John G. AuninsChief Technology Officer & EVPBuy10,000.0085,250.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/0000899243-18-031411-index.htm
2019-11-22Marcus ChapmanOfficerSell3,400.003.9113,296.728,600.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319028069/0000899243-19-028069-index.htm
2018-11-15John G. AuninsOfficerSell14,279.008.26117,911.7089,532.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318029310/0000899243-18-029310-index.htm
2019-01-26John G. AuninsChief Technology OfficerBuy7,500.0092,750.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002137/0000899243-19-002137-index.htm